{"organizations": [], "uuid": "a59797924263dcc539b6ca3fbaf14ec78110e6a6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180205.html", "section_title": "Archive News &amp; Video for Monday, 05 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-amag-pharmaceuticals-announces-fda/brief-amag-pharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-for-feraheme-idUSASB0C3XN", "country": "US", "domain_rank": 408, "title": "BRIEF-AMAG Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application (SNDA) For Feraheme", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.969, "site_type": "news", "published": "2018-02-05T21:27:00.000+02:00", "replies_count": 0, "uuid": "a59797924263dcc539b6ca3fbaf14ec78110e6a6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-amag-pharmaceuticals-announces-fda/brief-amag-pharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-for-feraheme-idUSASB0C3XN", "ord_in_thread": 0, "title": "BRIEF-AMAG Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application (SNDA) For Feraheme", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "amag pharmaceuticals", "sentiment": "negative"}, {"name": "brief-amag pharmaceuticals announces fda", "sentiment": "negative"}, {"name": "amag pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 5 (Reuters) - Amag Pharmaceuticals Inc:\n* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR FERAHEMEÂ® (FERUMOXYTOL INJECTION) Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-05T21:27:00.000+02:00", "crawled": "2018-02-07T00:01:53.001+02:00", "highlightTitle": ""}